Menevit Study: Menevit Anti-Oxidant Therapy for the Treatment of Male Infertility

Repromed60 enrolled

Overview

Oxidative stress related damage to sperm is believed to be a major cause of male infertility. The object of the Menevit study is to investigate the role of a novel anti-oxidant preparation (Menevit) on sperm function, embryo quality and pregnancy rates in an in vitro fertilization (IVF) setting.

Men will be screened for oxidative stress (free radical) related damage to their sperm. This will include screening for lipid peroxidation of sperm using the LPO-586 assay, HOST test and for sperm DNA fragmentation using the Tunel technique. Those men found to have free radical related damage will be enrolled in a randomized control trial in which they will receive either the Menevit anti-oxidant or placebo (in a 2:1 randomization ratio respectively). The Menevit anti-oxidant is a capsule containing several different anti-oxidants, taken orally once per day. The placebo is identical in appearance and taste. After 3 months of Menevit/placebo the female partners of these men will undergo an IVF oocyte retrieval operation and embryo transfer. Pregnancy rates and embryo quality will be compared between groups. Changes in semen characteristics (count, motility, morphology, membrane integrity) and lipid peroxidation (LPO-586) plus sperm DNA fragmentation (Tunel assay) will be assessed at trial entry, 6 weeks and 3 months. Comparisons between the patients embryo quality in the IVF cycle immediately before and during the Menevit trial will also be compared when possible

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Infertility, Male Oxidative Stress

Interventions

Menevit anti-oxidantDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Evidence of oxidative stress to sperm on LPO-586 assay or poor HOST result or clinical evidence for oxidative stress (heavy smoker, varicocele, poor motility in the abscence of anti-sperm antibodies etc) * Evidence of significant sperm DNA damage (25% or more DNA fragmentation as assessed by Tunel assay). * Female partner willing to undergo IVF treatment within 3 months of starting Menevit trial Exclusion Criteria: * Female partner 40 years of age or older at trial entry. * Significantly reduced ovarian reserve in female partner (day 3-5 FSH \> 10 iu/L if no prior IVF cycle or less than 5 oocytes on a prior IVF cycle. * Sperm count below 0.5 million per ml (impossible to conduct all sperm function assays

Locations (1)

Repromed

Adelaide, South Australia, Australia

Outcomes

Primary Outcomes

Embryo quality (morphology score, progression to blastocyst rates, number of embryos available for freezing/transfer per cycle)

Embryo quality is a good measure of pregnancy potential and is also an indicator of sperm DNA integrity, making it the ideal primary endpoint.

Secondary Outcomes

sperm DNA fragmentation

sperm count

sperm motility (total motile sperm per ejaculate)

sperm morphology

sperm membrane integrity (as assessed by hypo-osmolar swelling test)

levels of sperm lipid peroxidation (LPO-586 assay)

retrospective comparison of embryo quality between the Menevit IVF cycle and the preceding non-Menevit IVF cycle.

miscarriage rate (clinical and biochemical)

clinical pregnancy rates (number of fetal hearts seen on first trimester scan)

adverse side effects

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.